Product Images Dofetilide

This is a description of a medication in capsule form with the NDC number 51407-541-60. Each capsule contains 125 micrograms (0.125 mg) of dofetilide. The medication guide should be dispensed to each patient along with the prescription. It is important to store the capsules in a tight container away from moisture and humidity, and keep them out of reach of children. The recommended storage temperature is 15° - 30°C (59° - 86°F). The medication is marketed by GSMS, Incorporated.*

This text provides information about Dofetilide capsules, a medication prescribed by a pharmacist. Each capsule contains 250 mcg (0.25 mg) of Dofetilide. It instructs to dispense in a tight container, protect from moisture and humidity, and keep out of the reach of children. The medication should be stored at a controlled room temperature between 16° - 30°C (59° - 86°F).The marketing and contact details are mentioned for GSMS, Incorporated.*

This text provides information about Dofetilide capsules, each containing 500 mcg (0.5 mg) of dofetilide. It includes instructions for dosage, storage conditions (15° - 30°C), and guidance to dispense in a tight container to protect from moisture and humidity. The text also recommends keeping the medication out of reach of children. Additionally, it states that a Medication Guide should be provided to each patient and can be printed via a specific website. The capsules are to be marketed by GSMS, Incorporated in Camarillo, CA, USA.*

This text provides instructions for healthcare professionals regarding the use of telemetry for placing patients, monitoring QT interval and creatinine clearance levels, and dosing recommendations for dofetilide based on the calculated creatinine clearance. It also includes guidelines for dose adjustments based on QTc or QT changes post-dosing and highlights the importance of monitoring QT interval to ensure patient safety.*

This text provides information about a study involving Dofetilide at different doses (125mcg BID, 250mcg BID, and 500mcg BID) compared to a placebo. The p-values from the Log Rank Test for each dose are given as 0.21, 0.10, and <0.001, indicating the statistical significance of the results. The graph shows the Probability of Remaining in NSR over time in months (from Time 0 to 6).*

This description shows the probability of remaining in Normal Sinus Rhythm (NSR) over time. It includes results from a Log Rank Test for different dosages of a medication (125 mcg BID, 250 mcg BID, 500 mcg BID) with their corresponding p-values. The graph displays the data over a period of 0 to 12 months.*

This text provides data on the mean change from baseline QTc in milliseconds on Day 1 and Day 23 (Steady State) at various concentrations of plasma dofetilide. This information can be used to evaluate the impact of dofetilide concentration on QTc prolongation.*